Skip to main content
Top
Published in: Clinical and Experimental Nephrology 3/2010

01-06-2010 | Letter to the Editor

Coincident chronic inflammatory demyelinating polyneuropathy and focal segmental glomerulosclerosis: a common autoimmunity?

Authors: Francesca Girolami, Giuliana Galassi, Luciana Furci, Alessandra Ariatti, Gianni Cappelli

Published in: Clinical and Experimental Nephrology | Issue 3/2010

Login to get access

Abstract

A 40-year-old male developed swallowing difficulties, loss of strength, and imbalance. On admission, the patient exhibited bifacial, extremity weakness, ataxia, impaired sensation, and areflexia. Electrophysiology and nerve biopsy suggested demyelination. Spinal fluid revealed increased protein content. Plasmapheresis showed benefit, but neuropathy relapsed. At second recurrence, urine analysis showed heavy proteinuria. Renal biopsy revealed focal segmental glomerulosclerosis (FSGS). Methylprednisolone and oral cyclophosphamide were given. Long-term steroids and immunoglobulin showed steady benefit. Concurrence of chronic inflammatory demyelinating polyneuropathy and FSGS suggests synergistic cellular and humoral autoimmune mechanisms related to either cross-reactivity within antigenic targets or mimicry between neural and renal epitopes.
Literature
1.
go back to reference Romanick Schmiedl S, Kiprov DD, Chalmers A, Miller RG. Extraneural manifestations of chronic inflammatory demyelinating polyradiculoneuropathy. Am J Med. 1990;89:531–4.CrossRefPubMed Romanick Schmiedl S, Kiprov DD, Chalmers A, Miller RG. Extraneural manifestations of chronic inflammatory demyelinating polyradiculoneuropathy. Am J Med. 1990;89:531–4.CrossRefPubMed
2.
go back to reference Koller H, Schroeter M, Kieseier BC, Hartung HP. Chronic inflammatory demyelinating polyneuropathy-update on pathogenesis, diagnostic criteria and therapy. Curr Opin Neurol. 2005;18:273–8.CrossRefPubMed Koller H, Schroeter M, Kieseier BC, Hartung HP. Chronic inflammatory demyelinating polyneuropathy-update on pathogenesis, diagnostic criteria and therapy. Curr Opin Neurol. 2005;18:273–8.CrossRefPubMed
3.
go back to reference Olbricht CJ, Stark E, Helmchen U, et al. Glomerulonephritis associated with inflammatory demyelinating polyradiculoneuropathy: a case report and review of the literature. Nephron. 1993;64:139–41.CrossRefPubMed Olbricht CJ, Stark E, Helmchen U, et al. Glomerulonephritis associated with inflammatory demyelinating polyradiculoneuropathy: a case report and review of the literature. Nephron. 1993;64:139–41.CrossRefPubMed
4.
go back to reference Henderson RD, Healy HG, Mc Combe PA, Lander CM. Chronic inflammatory demyelinating polyradiculoneuropathy and severe peripheral oedema: a renal explanation. J Clin Neurosci. 2000;72:148–9.CrossRef Henderson RD, Healy HG, Mc Combe PA, Lander CM. Chronic inflammatory demyelinating polyradiculoneuropathy and severe peripheral oedema: a renal explanation. J Clin Neurosci. 2000;72:148–9.CrossRef
5.
go back to reference Smyth S, Menkes DL. Coincident membranous glomerulonephritis and chronic inflammatory demyelinating polyradiculoneuropathy: questioning the autoimmunity hypothesis. Muscle Nerve. 2008;37:130–5.CrossRefPubMed Smyth S, Menkes DL. Coincident membranous glomerulonephritis and chronic inflammatory demyelinating polyradiculoneuropathy: questioning the autoimmunity hypothesis. Muscle Nerve. 2008;37:130–5.CrossRefPubMed
Metadata
Title
Coincident chronic inflammatory demyelinating polyneuropathy and focal segmental glomerulosclerosis: a common autoimmunity?
Authors
Francesca Girolami
Giuliana Galassi
Luciana Furci
Alessandra Ariatti
Gianni Cappelli
Publication date
01-06-2010
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 3/2010
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-009-0259-2

Other articles of this Issue 3/2010

Clinical and Experimental Nephrology 3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.